Filing Details
- Accession Number:
- 0000899243-18-016286
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-06-12 20:26:44
- Reporting Period:
- 2018-06-08
- Accepted Time:
- 2018-06-12 20:26:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1160308 | Savara Inc | SVRA | Pharmaceutical Preparations (2834) | 841318182 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1703487 | N Robert Neville | 6836 Bee Cave Road, Building Iii Suite 200 Austin TX 78746 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-06-08 | 2,737 | $12.13 | 402,648 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2018-06-11 | 92,351 | $0.65 | 494,999 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-06-11 | 5,252 | $11.43 | 489,747 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2018-06-11 | 1,791 | $12.01 | 487,956 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-06-12 | 13,445 | $12.09 | 474,511 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-06-11 | 92,351 | $0.00 | 92,351 | $0.65 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2022-09-14 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2017.
- The price is a weighted average sale price. The sale prices ranged from $12.00 to $12.57. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price is a weighted average sale price. The sale prices ranged from $12.00 to $12.10. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price is a weighted average sale price. The sale prices ranged from $12.00 to $12.225. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The shares subject to the option vested and became exercisable in sixteen equal quarterly installments beginning on December 14, 2012.
- 7,269 shares subject to the option were previously exercised and transferred subject to a domestic relations order.
Billionaire Hedge Funds
